Skip to content
Markets News
Earnings1 min read

Laurus Labs Jumps as CDMO Growth Lifts Quarterly Profit

Makkler Newsroom
October 30, 2026 · Based on reporting by Business Standard, The Economic Times

The pharmaceutical company reported 33% revenue growth and a 126% rise in quarterly profit, with CDMO sales up 86%.

Key takeaways

  • Laurus Labs' Q2FY27 revenue rose 33% to ₹2,206 crore.
  • Net profit increased 126% year on year to ₹441 crore.
  • CDMO revenue grew 86% to ₹875 crore.
  • The company declared an interim dividend of ₹1 per share.

Laurus Labs reported a 126% year-on-year rise in Q2FY27 net profit to ₹441 crore, as revenue grew 33% to ₹2,206 crore. Its shares rose following the results.

The Economic Times reported EBITDA of ₹762 crore, up 78%, and an EBITDA margin of 34.5%. As of 06:48 UTC on Friday, the shares traded at ₹2,365, up 5.39% from the previous close.

Contract development and manufacturing organization (CDMO) revenue climbed 86% to ₹875 crore, according to Business Standard. Generic Formulations sales rose 31% to ₹677 crore, while Generic API revenue increased 1% to ₹625 crore.

Laurus Labs said its first commercial-scale peptide manufacturing plant in Vizag had been operationalised. The company also announced investments in oligonucleotides and peptide-resin technologies to expand its CDMO capabilities.

For the first half of FY27, revenue rose 31% to ₹4,233 crore and EBITDA reached ₹1,406 crore, the Economic Times reported. Laurus Labs also declared an interim dividend of ₹1 per share.

Further reading

This article was produced with the help of AI technology. Based on reporting by the outlets listed above.

Comments (0)

Log in to join the discussion.Log in

No comments yet - be the first to weigh in.